Stocks
Bristol-Myers Financial Statements (BMY) |
||||||||||
| Bristol-Myerssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.02.2020 | 10.02.2021 | 09.02.2022 | 14.02.2023 | 13.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 26 145 | 42 518 | 46 385 | 46 159 | 45 006 | 47 435 | |||
| Operating Income, bln rub | 5 464 | 5 128 | 10 159 | 10 328 | 16 598 | 12 717 | ||||
| EBITDA, bln rub | ? | 7 440 | 5 035 | 20 191 | 19 232 | 19 417 | 5 032 | |||
| Net profit, bln rub | ? | 3 439 | -8 995 | 6 994 | 6 327 | 8 025 | -7 258 | |||
| OCF, bln rub | ? | 8 067 | 14 052 | 16 207 | 13 066 | 13 860 | 15 003 | |||
| CAPEX, bln rub | ? | 836.0 | 753.0 | 973.0 | 1 118 | 1 209 | 1 200 | |||
| FCF, bln rub | ? | 7 231 | 13 299 | 15 234 | 11 948 | 12 651 | 13 803 | |||
| Dividend payout, bln rub | 2 679 | 4 075 | 4 396 | 4 634 | 4 744 | 4 805 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 77.9% | 0.00% | 62.9% | 73.2% | 59.1% | -66.2% | ||||
| OPEX, bln rub | 12 154 | 28 568 | 27 908 | 26 918 | 34 313 | 22 822 | ||||
| Cost of production, bln rub | 8 078 | 11 773 | 9 940 | 10 137 | 10 693 | 14 034 | ||||
| R&D, bln rub | 6 148 | 11 143 | 10 195 | 9 509 | 9 299 | 9 842 | ||||
| Interest expenses, bln rub | 656.0 | 1 420 | 1 334 | 1 232 | 1 166 | 1 767 | ||||
| Assets, bln rub | 129 944 | 118 481 | 109 314 | 96 820 | 95 159 | 93 670 | ||||
| Net Assets, bln rub | ? | 51 598 | 37 822 | 35 946 | 31 061 | 29 430 | 17 142 | |||
| Debt, bln rub | 47 538 | 51 673 | 45 596 | 40 717 | 41 464 | 51 400 | ||||
| Cash, bln rub | 12 346 | 14 546 | 13 979 | 9 123 | 12 280 | 8 094 | ||||
| Net debt, bln rub | 35 192 | 37 127 | 31 617 | 31 594 | 29 184 | 43 306 | ||||
| Ordinary share price, rub | 64.2 | 62.0 | 62.4 | 72.0 | 51.3 | 51.2 | ||||
| Number of ordinary shares, mln | 1 705 | 2 258 | 2 221 | 2 130 | 2 069 | 2 028 | ||||
| Market cap, bln rub | 109 444 | 140 064 | 138 479 | 153 254 | 106 160 | 103 874 | ||||
| EV, bln rub | ? | 144 636 | 177 191 | 170 096 | 184 848 | 135 344 | 147 180 | |||
| Book value, bln rub | -34 859 | -35 968 | -27 331 | -26 443 | -18 811 | -31 573 | ||||
| EPS, rub | ? | 2.02 | -3.98 | 3.15 | 2.97 | 3.88 | -3.58 | |||
| FCF/share, rub | 4.24 | 5.89 | 6.86 | 5.61 | 6.11 | 6.81 | ||||
| BV/share, rub | -20.4 | -15.9 | -12.3 | -12.4 | -9.09 | -15.6 | ||||
| EBITDA margin, % | ? | 28.5% | 11.8% | 43.5% | 41.7% | 43.1% | 10.6% | |||
| Net margin, % | ? | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -15.3% | |||
| FCF yield, % | ? | 6.61% | 9.49% | 11.0% | 7.80% | 11.9% | 13.3% | |||
| ROE, % | ? | 6.66% | -23.8% | 19.5% | 20.4% | 27.3% | -42.3% | |||
| ROA, % | ? | 2.65% | -7.59% | 6.40% | 6.53% | 8.43% | -7.75% | |||
| P/E | ? | 31.8 | -15.6 | 19.8 | 24.2 | 13.2 | -14.3 | |||
| P/FCF | 15.1 | 10.5 | 9.09 | 12.8 | 8.39 | 7.53 | ||||
| P/S | ? | 4.19 | 3.29 | 2.99 | 3.32 | 2.36 | 2.19 | |||
| P/BV | ? | -3.14 | -3.89 | -5.07 | -5.80 | -5.64 | -3.29 | |||
| EV/EBITDA | ? | 19.4 | 35.2 | 8.42 | 9.61 | 6.97 | 29.2 | |||
| Debt/EBITDA | 4.73 | 7.37 | 1.57 | 1.64 | 1.50 | 8.61 | ||||
| R&D/CAPEX, % | 735.4% | 1 480% | 1 048% | 850.5% | 769.1% | 820.2% | ||||
| CAPEX/Revenue, % | 3.20% | 1.77% | 2.10% | 2.42% | 2.69% | 2.53% | ||||
| Bristol-Myers shareholders | ||||||||||
